Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest TIMI Stories

2014-04-01 08:28:03

'Hubs' offer personal health consultations, blood draws and group classes in a modern, stylish environment RICHMOND, Va., April 1, 2014 /PRNewswire/ -- Health Diagnostic Laboratory, Inc. is taking the next step in its mission to detect, prevent and reverse major chronic disease such as heart disease and diabetes with the launch of My HDL Hub health centers. HDL, Inc.'s My HDL Hub is a place for individuals to receive comprehensive blood tests, gain lifestyle, nutrition and fitness...

2014-02-24 08:28:05

Patient Recruitment and Enrollment Now Underway WOODCLIFF LAKE, N.J., Feb. 24, 2014 /PRNewswire/ -- Eisai Inc. today announced that patient recruitment and enrollment are currently underway for CAMELLIA-TIMI 61, a randomized double-blind, placebo-controlled outcomes trial to evaluate the effect of long-term treatment with lorcaserin HCl on the incidence of major adverse cardiovascular events and new onset type 2 diabetes mellitus in obese (BMI > 30 kg/m(2)) and overweight (BMI > 27...

2014-02-05 11:28:09

In an analysis of blood pressure patterns over a 25-year span from young adulthood to middle age, individuals who exhibited elevated and increasing blood pressure levels throughout this time period had greater odds of having higher measures of coronary artery calcification (a measure of coronary artery atherosclerosis), according to a study in the February 5 issue of JAMA. "Blood pressure (BP) represents a major modifiable risk factor for cardiovascular disease (CVD). Current risk...

2013-11-25 08:27:45

- Corus® CAD Gene Expression Test Impacts Clinical Decision-Making in Primary Care Practices and Reduces Unnecessary Referrals for Cardiac Testing in this Special Population - PALO ALTO, Calif., Nov. 25, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced results from a multi-center, real-world registry study highlighting the clinical utility of Corus(®) CAD in evaluating suspected obstructive coronary artery...

2013-10-21 08:29:25

- Corus® CAD is Effective in Excluding the Diagnosis of Obstructive Coronary Artery Disease in the Primary Care Setting and Helps Reduce Unnecessary Healthcare Expense - PALO ALTO, Calif., Oct. 21, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced results of a multi-center, real-world registry study demonstrating the clinical utility of Corus® CAD, a blood-based gene expression test, in the evaluation of...

2013-10-10 08:29:32

- Corus® CAD Has Potential to Reduce Cardiac Diagnostic Costs in Women by More Than $500 per Patient - PALO ALTO, Calif., Oct. 10, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced results of two studies indicating that Corus(®) CAD, a blood-based gene expression test, may help reduce unnecessary cardiac testing and costs by aiding clinician decision-making in the evaluation of women with symptoms...

Medical Trials Offer Positive Results For Specific Class Of Diabetes Drug
2013-09-03 07:59:01

redOrbit Staff & Wire Reports - Your Universe Online While a new class of diabetes pill known as DPP-4 inhibitors does not appear to increase a person’s risk of heart attack, there is some indication that there could be other negative cardiovascular effects associated with the drugs. According to Reuters reporter Ben Hirschler, some of the medications – which are a class of oral hypoglycemics that block a protein that plays a major role in glucose metabolism – were linked to a...

2013-08-26 16:23:34

- Sex-Specific Blood-based Genomic Test Helps Exclude the Diagnosis of Obstructive CAD in Symptomatic Patients - PALO ALTO, Calif., Aug. 26, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of a comprehensive review of the evidence demonstrating that Corus(®) CAD, a blood-based gene expression test, can help clinicians accurately and safely exclude obstructive coronary artery disease (CAD)...

2013-05-02 08:31:56

SAN DIEGO, May 2, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced a publication, "Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors", authored by Gabor M Rubanyi, M.D., Ph.D., Cardium's Chief Scientific Officer in the April issue of Molecular Therapy. The publication outlines current scientific knowledge about the mechanistic basis of adaptive coronary collateral growth, the...

2013-01-29 08:31:28

SAN DIEGO, Jan. 29, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced a presentation at the 2013 Phacilitate Annual Cell & Gene Therapy Forum in Washington, DC. The Company's presentation, "Optimizing Phase III Trial Design for Generx® (Ad5FGF-4)" by Cardium's Chief Scientific Officer, Gabor M. Rubanyi, M.D., Ph.D. outlined the current scientific knowledge about the mechanistic basis of adaptive coronary collateral growth, the biological processes to be...